Phytotide CRF Cellular Renewal Factor 5 Ampoules

Cellular Renewal Factor for deep skin rejuvenation. Suitable for post treatment care and professional infusion.

NO FACE Clinical Trial Extract

This study evaluates the efficacy of a combination therapy using tranexamic acid and peptides in mitigating signs of UV induced skin ageing. Conducting a double blinded, controlled investigation, we enlisted a participant pool of 12 candidates, split into two groups to rigorously assess the aesthetic impact of this innovative combination therapy. Over a course of four months, with treatments administered every 4 weeks, we meticulously analyzed the biochemical mechanisms at play, particularly focusing on how tranexamic acid and peptides synergistically influence melanin synthesis, collagen formation, and skin repair processes at a cellular level. A follow up period of 3 months post treatment allowed for the evaluation of reasonable treatment effects, with particular attention to the sustainability of improvements in hyperpigmentation, elasticity, and overall skin texture. This follow up period provided insights into the long term benefits and potential side effects of combining tranexamic acid and peptides in combating the multifaceted process of UV skin ageing. Our preliminary findings suggest that this combination not only offers a potential corrective measure for existing UV damage but also imparts protective advantages against future photodamage, marking an advancement in anti-ageing dermatological treatment.

The primary objective of this study is to systematically evaluate the combined effects of tranexamic acid and peptides on signs of UV skin ageing. By employing a comprehensive approach, the study aims to elucidate the mechanisms through which this combination therapy improves skin health, specifically targeting hyperpigmentation, loss of elasticity, and texture irregularities caused by UV exposure. The research seeks to affirm the potential of tranexamic acid and peptides as a viable, multifaceted treatment option for photoaged skin, offering insights into its long-term benefits and optimizing dermatological interventions against UV-induced skin ageing.

TXA

Tranexamic acid (TXA), a synthetic derivative of the amino acid lysine, has been widely recognized for its antifibrinolytic properties. Over the past few decades, its application has expanded beyond hemostasis, garnering attention for its potential in treating hyperpigmentation disorders, notably melasma. This literature review explores the efficacy of TXA in dermatology, with a focus on its skin-lightening effects in treating melasma and other pigmentation conditions.

Mechanism of Action

TXA's mechanism in treating hyperpigmentation is attributed to its ability to inhibit the plasminogen activation pathway. Plasmin, when activated, can stimulate melanocytes to produce melanin. By inhibiting this pathway, TXA reduces melanin synthesis, contributing to its depigmenting effects [1][2].

Efficacy in Treating Melasma

A pivotal study by Kanechorn Na Ayuthaya et al. (2012)[3] demonstrated the effectiveness of topical TXA in melasma treatment, with patients showing significant improvement in the Melasma Area and Severity Index (MASI) scores. Similarly, Lee et al. (2016)[4] reported improvements in melasma with oral TXA administration over a period of 12 weeks, underscoring its potential as a systemic treatment option.

sh-Oligopeptide-1

sh-Oligopeptide-1, also known as Epidermal Growth Factor (EGF), plays a pivotal role in the skin's healing processes and regeneration. It is a potent signaling molecule that binds to the epidermal growth factor receptor (EGFR) on the surface of skin cells, initiating a cascade of cellular activities that promote cell growth, proliferation, and differentiation [9].

Biochemical Properties and Mechanisms of Action

Promotion of Cellular Regeneration: sh-Oligopeptide-1 stimulates keratinocyte and fibroblast proliferation, which are essential for the repair of the epidermal and dermal layers of the skin damaged by UV radiation [10].

Enhancement of Collagen Production: By promoting fibroblast activity, it facilitates the synthesis of collagen, a critical component of the skin's structural matrix, which is often degraded by cumulative UV exposure [11].

Wound Healing and Reduction of Inflammation: EGF has been shown to accelerate wound healing processes, including those initiated by UV-induced skin damage, while also modulating inflammatory responses that are exacerbated by UV exposure [12].

Copper Peptide

Copper peptides, specifically GHK-Cu (glycyl-l-histidyl-l-lysine-copper), are small, naturally occurring protein fragments that have a strong affinity for copper ions. Copper is a trace element involved in various biological processes, including the activation of enzymes important for skin health and repair.

Biochemical Properties and Mechanisms of Action

Stimulation of Collagen and Elastin Production: Copper peptides have been found to activate the synthesis of collagen and elastin, counteracting the degradation of these fibrous proteins by UV radiation, thereby improving skin elasticity and reducing the appearance of wrinkles [13].

Antioxidant Properties: They possess potent antioxidant properties, scavenging free radicals generated by UV exposure that contribute to oxidative stress and cellular damage in skin tissues [14].

Angiogenesis and Wound Healing: Copper peptides promote angiogenesis, enhancing blood flow to damaged areas of the skin, which supports the delivery of nutrients and oxygen necessary for tissue repair and regeneration following UV damage [15].

Study Design

This clinical trial is designed as a randomized, double blinded, controlled study involving 12 participants, equally divided by gender (6 women and 6 men) and ranging in age from 35 to 65 years. The inclusion of individuals across all Fitzpatrick skin phototypes (1-6) ensures a diversified demographic, enhancing the study's robustness and the generalizability of its findings. Participants are randomly assigned to one of two groups: Group A, which receives the treatment with Phytotide CRF formulation, and Group B, which receives a placebo treatment during the microneedling procedure.

Treatment Protocol

Microneedling Procedure

The microneedling procedure is performed using a Medifacial Infusionderm roller device equipped with 1.5mm microneedles. This device is chosen for its ability to create controlled micro-injuries to the skin, thereby stimulating the body's natural wound healing processes and enhancing the penetration of topical formulations. In this study, the microneedling procedure is conducted 4 weeks apart, for 4 treatments.  

Quantitative Findings

The clinical trial aimed to evaluate the efficacy of a combined treatment of tranexamic acid and peptides in addressing hyperpigmentation, pore size, and wrinkles in individuals with UV-damaged skin. The study involved a detailed statistical analysis to assess the improvements in these parameters, utilizing confidence intervals and significance levels to ensure the reliability of the findings.

Hyperpigmentation: Participants in Group A (treated with Phytotide CRF) showed a significant reduction in the Melasma Area and Severity Index (MASI) scores, with an average decrease of 36% (95% CI: 28-44%, p < 0.05) post-treatment. (P1) In contrast, Group B (placebo group) reported a minimal change, with an average reduction of 5% (95% CI: -2 to 12%, p > 0.05).

Pore Size: Analysis of pore size reduction revealed an average decrease of 15% (95% CI: 9-21%, p < 0.05) in Group A, with the largest pore size reduction observed from 1.1mm to 0.6mm in diameter (P2), whereas Group B observed a non-significant change of 3% (95% CI: -1 to 7%, p > 0.05).

Wrinkles: The assessment of wrinkle depth using a validated wrinkle severity rating scale demonstrated a 24% improvement in Group A (95% CI: 16-32%, p < 0.01). Group B showed a negligible improvement of 4% (95% CI: -3 to 11%, p > 0.05).